85310-69-6

Basic information

• Product Name: (R)-(+)-3-(hydroxymethyl)pyrrolidine
• CAS NO: 85310-69-6
• Molecular Weight: 101.148
• Mol File: 85310-69-6.mol

Chemical Properties

• CAS DataBase Reference: (R)-(+)-3-(hydroxymethyl)pyrrolidine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-(+)-3-(hydroxymethyl)pyrrolidine(85310-69-6)
• EPA Substance Registry System: (R)-(+)-3-(hydroxymethyl)pyrrolidine(85310-69-6)

Safety Data

• Hazardous Substances Data: 85310-69-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(R)-(+)-3-(hydroxymethyl)pyrrolidine is used as a key intermediate for the synthesis of various pharmaceutical compounds. Its ability to be modified and functionalized allows for the creation of complex organic molecules that can be tailored for specific therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, (R)-(+)-3-(hydroxymethyl)pyrrolidine is employed as a vital component in the development of new agrochemical products. Its versatility in synthesis contributes to the design and production of effective and targeted agrochemicals.
Used in Asymmetric Synthesis:
(R)-(+)-3-(hydroxymethyl)pyrrolidine is used as a chiral auxiliary in asymmetric synthesis to control the stereochemistry of chemical reactions. This application is crucial for obtaining specific enantiomers of chiral molecules, which can have different biological activities and properties.
Used in Organic Synthesis Research:
As a versatile intermediate, (R)-(+)-3-(hydroxymethyl)pyrrolidine is also used in the field of organic synthesis research. It aids in the exploration of new synthetic pathways and the development of novel compounds with potential applications in various industries.

Upstream product

• 5733-86-8 1-benzyl-5-oxopyrrolidine-3-carboxylic acid 
• 5731-17-9 1-(Phenylmethyl)-3-pyrrolidinemethanol 
• 7440-44-0 pyrographite 
• 915302-94-2 (3RS)-1-<(R)-1-phenylethyl>-5-oxo-3-pyrrolidinecarboxylic acid 
• 96449-93-3 (R)-5-Oxo-1-((S)-1-phenyl-ethyl)-pyrrolidine-3-carboxylic acid 
• 138108-72-2 tert-butyl (R)-3-hydroxymethylpyrrolidine-1-carboxylate 
• 99735-45-2 methyl (3R)-1-<(R)-1-phenylethyl>-5-oxo-3-pyrrolidinecarboxylate 
• 192214-03-2 (R)-1-Benzyl-4-benzyloxymethyl-pyrrolidin-2-one 
• 192214-01-0 Toluene-4-sulfonic acid (S)-5-oxo-tetrahydro-furan-3-ylmethyl ester 
• 192214-02-1 β-azidomethyl γ-butyrolactone 
• 172796-28-0 (R)-4-((benzyloxy)methyl)dihydrofuran-2(3H)-one 
• 85701-08-2 (R)-4-(hydroxymethyl)dihydrofuran-2(3H)-one 
• 428518-36-9 methyl (R)-(-)-1-(phenylmethyl)-5-oxo-3-pyrrolidinecarboxylate 
• 617-52-7 Dimethyl itakonate 

Downstream Products

• 1251297-15-0 C₁₂H₁₄N₂O 
• 5731-17-9 1-(Phenylmethyl)-3-pyrrolidinemethanol 
• 1147529-19-8 4-tert-butyl-N-(2-methyl-3-{1-methyl-6-oxo-5-[2-(pyrrolidin-3-ylmethoxy)-pyrimidin-4-ylamino]-1,6-dihydro-pyridazin-3-yl}-phenyl)-benzamide 
• 1307881-21-5 (+/-)-N-carbobenzoxy-3-sulfamoyloxymethylpyrrolidine 
• 1307881-22-6 (+/-)-3-sulfamoyloxymethyl-N-(toluene-4-sulfonyl)pyrrolidine 
• 878013-26-4 (R)-[1-(4-bromophenyl)pyrrolidin-3-yl]methanol 
• 138108-72-2 tert-butyl (R)-3-hydroxymethylpyrrolidine-1-carboxylate 
• 1593181-81-7 C₁₉H₂₂N₂O₂ 

Relevant articles and documents

Discovery of phenylpyrrolidine derivatives as a novel class of retinol binding protein 4 (RBP4) reducers

Retinol-binding protein 4 (RBP4) is a potential drug target for metabolic and ophthalmologic diseases. A high-throughput screening of our compound library has identified a small-molecule RBP4 reducer 7a, as a hit compound. Aiming to provide a suitable too

Preparation method of chiral 3-substituted pyrrolidine derivative

The invention provides a preparation method of a chiral 3-substituted pyrrolidine derivative. The preparation method comprises an intermediate preparation step, a diastereomer mixture preparation step, a chiral separation step and a chiral 3-substituted pyrrolidine derivative synthesis step. According to the invention, through catalytic asymmetric kinetic resolution, a mixture of two diastereoisomers is efficiently converted into a diastereoisomer with a certain single configuration, chiral separation is realized, a key intermediate is obtained with high yield, and a series of chiral 3-substituted pyrrolidine derivatives are synthesized. The whole reaction route is mild in reaction condition, simple and convenient to operate, high in resolution efficiency, high in atom economy, low in costand suitable for industrial scale production.

Method for synthesizing N-Boc-3-pyrrolidine formaldehyde

The invention discloses a method for synthesizing N-Boc-3-pyrrolidine formaldehyde. The method comprises that dimethyl itaconate as a raw material undergoes an intramolecular cyclization reaction to produce methyl 5-oxo-3-pyrrolidine carboxylate, then the methyl 5-oxo-3-pyrrolidine carboxylate undergoes a reduction reaction to produce pyrrolidine-3-methanol, then the pyrrolidine-3-methanol is subjected to Boc protection so that N-Boc-pyrrolidine-3-methanol is obtained, and finally, the N-Boc-pyrrolidine-3-methanol is oxidized to form a final product compound. The method is simple and convenient, has a low cost, content greater than 99%, produces small environmental pollution and is suitable for industrial production.

Concise synthesis of bicyclic aminals by way of catalytic intramolecular C-H amination and evaluation of their reactivity as iminium precursors

The concise synthesis of fused bicyclic aminals by way of intramolecular rhodium-catalyzed C-H amination is reported as well as the evaluation of their reactivity as iminium precursors. In contrast to the well-studied N,O-acetal systems, the aminals synthesized were found to be particularly stable under reaction conditions used for nucleophilic addition.

AURORA KINASE COMPOUNDS AND METHODS OF THEIR USE

Provided herein are pyrrolotriazine compounds for treatment of Aurora kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

Iron(III)-catalyzed consecutive aza-cope-mannich cyclization: Synthesis of trans -3,5-dialkyl pyrrolidines and 3,5-dialkyl-2,5-dihydro-1 H-pyrroles

An efficient alkene aza-Cope-Mannich cyclization between 2-hydroxy homoallyl tosylamine and aldehydes in the presence of iron(III) salts to obtain 3-alkyl-1-tosyl pyrrolidines in good yields is described. The process is based on the consecutive generation of a γ-unsaturated iminium ion, 2-azonia-[3,3]-sigmatropic rearrangement, and further intramolecular Mannich reaction. Iron(III) salts are also shown to be excellent catalysts for the new aza-Cope-Mannich cyclization using 2-hydroxy homopropargyl tosylamine.

Disubstituted pyrimidines as Lck inhibitors

We have developed a family of 4-benzimidazolyl-N-piperazinethyl-pyrimidin-2-amines that are subnanomolar inhibitors of Lck. A subset of these Lck inhibitors, with heterocyclic substituents at the benzimidazole C5, are also low-nanomolar inhibitors of cell

Evaluation of structurally diverse neuronal nicotinic receptor ligands for selectivity at the α6* subtype

Direct comparison of pyridine versus pyrimidine substituents on a small but diverse set of ligands indicates that the pyrimidine substitution has the potential to enhance affinity and/or functional activity at α6 subunit-containing neuronal nicotinic rece

QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS

A quinazoline derivative of the formula (I): (A chemical formula should be inserted here - please see paper copy enclosed) Formula I wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.

QUINOLONE ANTIBACTERIAL AGENTS

Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formula I. Compounds of formula I as disclosed herein can be used in a variety of applications including use as antibacterial agents.